On Thanksgiving Day, BD Diagnostics announced it had received CE Mark approval for the BD MAX MRSA assay, which is designed to rapidly and accurately identify methicillin-resistant Staphylococcus aureus in patients. The assay is the first fully automated, bench-top molecular system that performs a range of molecular testing, the company says in a release.
The company plans to develop additional assays for the BD MAX system for a range of disease categories, according to Tom Polen, president, BD Diagnostics, diagnostic systems. There are now more than 20 assays in the BD MAX system's pipeline.
"The challenge to fight healthcare-associated infections in Europe is resulting in an increased number of active surveillance programs for MRSA in a continually resource-constrained environment," explains Hilja Ibert, VP and general manager, BD Diagnostics, diagnostic systems in Europe. "The BD MAX MRSA Assay on the BD MAX System provides significant laboratory efficiency and versatility to help address the increasing volume of molecular tests."
- see the BD release
Special Report: Becton Dickinson - Top 10 Medical Device Companies